Last reviewed · How we verify
Cantharidin solution
At a glance
| Generic name | Cantharidin solution |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) (PHASE3)
- Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women (EARLY_PHASE1)
- Cantharidin and Occlusion in Verruca Epithelium (PHASE2)
- A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts (PHASE2)
- Cantharidin Application in Molluscum Patients-1 (PHASE3)
- Cantharidin Application in Molluscum Patients (PHASE3)
- Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. (PHASE2)
- First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cantharidin solution CI brief — competitive landscape report
- Cantharidin solution updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI